Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 274-283

  Thakur, Ankita ^a   Joshi, Nitin ^a   Shanmugam, Thanigaivel ^a   Banerjee, Rinti ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Blood brain barrier; Glioblastoma multiforme; Intranasal; Lipid nanovesicles; Miltefosine; Paclitaxel

Indexed keywords

ADENOSINE TRIPHOSPHATE; CLATHRIN; LIPOSOME; MILTEFOSINE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG UPTAKE; ENCAPSULATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; MUCOADHESION; NONHUMAN; NOSE MUCUS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; NANOSTRUCTURES; PACLITAXEL; PHOSPHORYLCHOLINE; RATS; RATS, WISTAR;

EID: 84878240721     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.022     Document Type: Article

References (49)

1. Hashizume R., Ozawa T., Gryaznov S.M., Bollen A.W., Lamborn K.R., Frey W.H., Deen D.F. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro. Oncol. 2008, 10:112-120.
2. Ozawa T., Afzal J., Lamborn K.R., Bollen A.W., Bauer W.F., Koo M.-S., Kahl S.B., Deen D.F. Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:247-252.
3. MacKay J.A., Deen D.F., Szoka F.C. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. 2005, 1035:139-153.
4. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA 1994, 91:2076-2080.
5. Groothuis D.R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro. Oncol. 1999, 2:45-59.
6. Patel S., Chavhan S., Soni H., Babbar A.K., Mathur R., Mishra A.K., Sawant K. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J. Drug Target. 2010, 19:468-474.
7. Wang F., Jiang X., Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int. J. Pharm. 2003, 263:1-7.
8. Wang D., Gao Y., Yun L. Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother. Pharmacol. 2006, 57:97-104.
9. Sakane T., Yamashita S., Yata N., Sezaki H. Transnasal delivery of 5-fluorouracil to the brain in the rat. J. Drug Target. 1999, 7:233-240.
10. Gao X., Tao W., Lu W., Zhang Q., Zhang Y., Jiang X., Fu S. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006, 27:3482-3490.
11. Rittierodt M., Tschernig T., Harada K. Modulation of multidrug-resistance-associated P-Glycoprotein in human U-87 MG and HUV-ECC Cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology 2004, 71:123-128.
12. Bandak S., Goren D., Horowitz A., Tzemach D., Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 1999, 10:911-920.
13. Crosasso P., Ceruti M., Brusa P., Arpicco S., Dosio F., Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Controlled Release 2000, 63:19-30.
14. Eliaz R.E., Szoka F.C. Liposome-encapsulated doxorubicin targeted to CD44. Cancer Res. 2001, 61:2592-2601.
15. Zhang L.-J., Xing B., Wu J., Xu B., Fang X.-L. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Pulm. Pharmacol. Ther. 2008, 21:239-246.
16. Arumugam K., Subramanian G., Mallayasamy S., Averineni R., Reddy M., Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008, 58:287-297.
17. Migliore M.M., Vyas T.K., Campbell R.B., Amiji M.M., Waszczak B.L. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J. Pharm. Sci. 2010, 99:1745-1761.
18. Papahadjopoulos D., Poste G., Vail W.J., Biedler J.L. Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor Cells. Cancer Res. 1976, 36:2988-2994.
19. Warren L., Jardillier J.-C., Malarska A., Akeli M.-G. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes. Cancer Res. 1992, 52:3241-3245.
20. Zhang J.A., Anyarambhatla G., Ma L., Ugwu S., Xuan T., Sardone T., Ahmad I. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. 2005, 59:177-187.
21. Papagiannaros A., Hatziantoniou S., Lelong-rebel I.H., Papaioannou G.T., Dimas K., Demetzos C. Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on scid mice. In Vivo 2006, 20:129-135.
22. Wieder T., Orfanos C.E., Geilen C.C. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J. Biol. Chem. 1998, 273:11025-11031.
23. Ghosh M., Bhattacharyya D. Soy lecithin-monoester interchange reaction by microbial lipase. J. Am. Oil Chem. Soc. 1997, 74:761-763.
24. Rittierodt M., Tschernig T., Harada K. Modulation of multidrug-resistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA. Pathobiology 2004, 71:123-128.
25. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13:238-252.
26. Egerdie B., Singer M. Morphology of gel state phosphatidylethanolamine and phosphatidylcholine liposomes: a negative stain electron microscopic study. Chem. Phys. Lipids 1982, 31:75-85.
27. Joshi N., Shanmugam T., Kaviratna A., Banerjee R. Proapoptotic lipid nanovesicles: synergism with paclitaxel in human lung adenocarcinoma A549 cells. J. Controlled Release 2011, 156:413-420.
28. A.A. Vipra, S.N. Desai, P. Roy, R. Patil, J.M. Raj, N. Narasimhaswamy, V.D. Paul, R. Chikkamadaiah, B. Sriram, Antistaphylococcal activity of bacteriophage derived chimeric protein P128, BMC Microbiol. doi:10.1186/1471-2180-12-41.
29. Rytter A., Cronberg T., Asztely F., Nemali S., Wieloch T. Mouse hippocampal organotypic tissue cultures exposed to in vitro "ischemia" show selective and delayed CA1 damage that is aggravated by glucose. J. Cereb. Blood Flow Metab. 2003, 23:23-33.
30. Vanhoefer U., Cao S., Harstrick A., Seeber S., Rustum Y.M. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann. Oncol. 1997, 8:1221-1228.
31. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
32. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 1994, 86:1517-1524.
33. McCloskey D.E., Kaufmann S.H., Prestigiacomo L.J., Davidson N.E. Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. Clin. Cancer Res. 1996, 2:847-854.
34. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
35. Vredenburg M.R., Ojima I., Veith J., Pera P., Kee K., Cabral F., Sharma A., Kanter P., Greco W.R., Bernacki R.J. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J. Natl. Cancer Inst. 2001, 93:1234-1245.
36. Cryan S.-A., Devocelle M., Moran P.J., Hickey A.J., Kelly J.G. Increased intracellular targeting to airway cells using octaarginine-coated liposomes: in vitro assessment of their suitability for inhalation. Mol. Pharm. 2005, 3:104-112.
37. Ramoino P., Gallus L., Beltrame F., Diaspro A., Fato M., Rubini P., Stigliani S., Bonanno G., Usai C. Endocytosis of GABAB receptors modulates membrane excitability in the single-celled organism paramecium. J. Cell Sci. 2006, 119:2056-2064.
38. Li R.-J., Ying X., Zhang Y., Ju R.-J., Wang X.-X., Yao H.-J., Men Y., Tian W., Yu Y., Zhang L., Huang R.-J., Lu W.-L. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J. Controlled Release 2011, 149:281-291.
39. Kuromi H., Yoshihara M., Kidokoro Y. An inhibitory role of calcineurin in endocytosis of synaptic vesicles at nerve terminals of Drosophila larvae. Neurosci. Res. 1997, 27:101-113.
40. Kitchens K.M., Kolhatkar R.B., Swaan P.W., Ghandehari H. Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol. Pharm. 2008, 5:364-369.
41. Di L., Kerns E.H., Fan K., McConnell O.J., Carter G.T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 2003, 38:223-232.
42. Mistry A., Stolnik S., Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 2009, 379:146-157.
43. Park S.-J., Wu C.-H., Gordon J.D., Zhong X., Emami A., Safa A.R. Taxol induces caspase-10-dependent apoptosis. J. Biol. Chem. 2004, 279:51057-51067.
44. Chavanpatil M.D., Khdair A., Gerard B., Bachmeier C., Miller D.W., Shekhar M.P.V., Panyam J. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol. Pharm. 2007, 4:730-738.
45. Fellner S., Bauer B., Miller D.S., Schaffrik M., Fankhanel M., Spruss T., Bernhardt G., Graeff C., Farber L., Gschaidmeier H., Buschauer A., Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 2002, 110:1309-1318.
46. Dorlo T.P., Eggelte T.A., de Vries P.J., Beijnen J.H. Characterization and identification of suspected counterfeit miltefosine capsules. Analyst 2012, 137:1265-1274.
47. Rey Gómez-Serranillos I., Miñones J., Dynarowicz-Łatka P., Miñones J., Iribarnegaray E. Miltefosine-cholesterol interactions: a monolayer study. Langmuir 2003, 20:928-933.
48. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 2001, 299:483-493.
49. Bardelmeijer H.A., Beijnen J.H., Brouwer K.R., Rosing H., Nooijen W.J., Schellens J.H.M., Tellingen O.v. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Can. Res. 2000, 6:4416-4421.